Investigators at the University of North Carolina say they have nailed down some solid preclinical evidence to suggest that the Dicer enzyme could be a good target for developers looking to advance new treatments for brain cancer.
Sun Pharmaceutical of India has signed a deal with an institute in Israel and one in Spain to develop treatments for neurological diseases like strokes and the brain cancer glioblastoma.
Scientists at The University of Texas MD Anderson Cancer Center have found that primary tumor cells with otherwise normal expression of a tumor suppressor--PTEN--lose PTEN expression specifically in the brain but not in other organs.
A global team of scientists working with Johns Hopkins' Jordan Green has developed a new nonviral gene therapy for brain cancer, successfully testing it in the lab in cell lines as well as rat models for the disease.
Mutations in the TCF12 gene, which plays a big role in developing brains in the embryo, has been tied to an aggressive form of brain cancer.
Researchers in Los Angeles have developed a nanomed that can take on two crucial roles--diagnosing brain tumors and delivering the drugs that can take them down.
Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut--more formally called Rintega and less formally "rindo"--provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.
Researchers at Northwestern University have put together a nanostructure capable of shuttling a new RNA molecule across the blood-brain barrier to reach tumor cells in mice with glioblastoma multiforme, a particularly aggressive form of brain cancer.
Zeroing in on an enzyme that is over-expressed in brain tumor cells, two investigators at Houston Methodist say they have developed a new treatment for gliomas that has cleared its preclinical testing and should be ready for human testing within the next one to two years.
Investigators say that they've identified a pathway that can be used to target brain tumor stem cells, adding to potential therapeutic strategies for the aggressive disease glioblastoma.